Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA

Michael Offin, Jacob J. Chabon, Pedram Razavi, James M. Isbell, Charles M. Rudin, Maximilian Diehn, and Bob T. Li

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305, USA
Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA
Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA

Correspondence should be addressed to Bob T. Li; lib1@mskcc.org

Received 6 January 2017; Accepted 28 February 2017; Published 14 March 2017

Academic Editor: Subodh Kumar

Copyright © 2017 Michael Offin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Genetic sequencing of malignancies has become increasingly important to uncover therapeutic targets and capture the tumor’s dynamic changes to drug sensitivity and resistance through genomic evolution. In lung cancers, the current standard of tissue biopsy at the time of diagnosis and progression is not always feasible or practical and may underestimate intratumoral heterogeneity. Technological advances in genetic sequencing have enabled the use of circulating tumor DNA (ctDNA) analysis to obtain information on both targetable mutations and capturing real-time Darwinian evolution of tumor clones and drug resistance mechanisms under selective therapeutic pressure. The ability to analyze ctDNA from plasma, CSF, or urine enables a comprehensive view of cancers as systemic diseases and captures intratumoral heterogeneity. Here, we describe these recent advances in the setting of lung cancers and advocate for further research and the incorporation of ctDNA analysis in clinical trials of targeted therapies. By capturing genomic evolution in a noninvasive manner, liquid biopsy for ctDNA analysis could accelerate therapeutic discovery and deliver the next leap forward in precision medicine for patients with lung cancers and other solid tumors.

In the current era of precision medicine, molecularly targeted therapies against oncogene driven lung cancers have been shown to achieve initial response rates of up to 70% [1]. Unfortunately, these medications inevitably fail over time due to the emergence of acquired resistance [2, 3]. These resistance mechanisms may emerge and persist through Darwinian evolution of tumor clones under therapeutic pressure [4]. The selective pressure favoring drug resistant malignant clones during treatment may alter the molecular profiles of tumors and their associated drug sensitivities, necessitating repeat biopsies to help guide further therapy. However, repeat biopsies are often impractical for patients and may fail to adequately reflect intratumoral heterogeneity, both of which represent substantial impediments to clinical care and therapeutic advances [5]. Recent technological advances in sequencing of circulating tumor DNA (ctDNA) have enabled the identification of tumor derived somatic alterations from plasma, urine, and cerebrospinal fluid (CSF) with high degrees of sensitivity and specificity [6, 7]. These advances comprise a unique opportunity to uncover novel mechanisms of acquired resistance to targeted therapies and capture genomic evolution in patients with molecular subsets of lung cancers in a noninvasive and universally obtainable way, the “liquid biopsy” (Figure 1). Liquid biopsies can be obtained with relative ease from plasma (blood volume needed: 10–20 mL) [8], lumbar puncture (CSF needed: 1-2 mL) [6, 9], or urine (urinary volume needed: 30–50 mL) [10]. Once the liquid biopsy is obtained,
the cell-free DNA (cfDNA) can be extracted and analyzed for tumor-specific alterations using any of a variety of techniques. Digital polymerase chain reaction (PCR) and next generation sequencing (NGS) are the primary methods of cfDNA analysis. Two of the most common digital-PCR based methods are Droplet Digital PCR (ddPCR) and BEAMing (beads, emulsions, amplification, and magnets) [11, 12]. Both of these methods leverage emulsion PCR, in which droplets containing individual DNA fragments are generated, allowing for DNA molecules to be amplified independently of one another. Sequences differentiating fluorescently labeled probes are then used to distinguish droplets containing mutant or wild-type alleles of interest. Counting of individual droplets enables more precise quantitation of mutant allele fractions than traditional reverse transcriptase-PCR (RT-PCR) based approaches [13]. In contrast, hybrid capture NGS selects the portions of the genome containing reference oncogenic mutations prior to sequencing to enrich the yield of the assay. Briefly, whole genome DNA libraries are generated from cell-free DNA via ligation of adapters and PCR. The genomic regions of interest are then selected out of the amplified libraries by hybridization capture using oligonucleotides or “baits” complementary to these regions, for subsequent enrichment. After another round of PCR, the enriched libraries are sequenced [14]. Another method, amplicon-based NGS, utilizes a multiplexed PCR to create a pool of amplified oligo-set primers which can be used to label a variety of target regions for “hotspots” of recurrent somatic mutations [15].

Each analysis method has its own diagnostic niche. Digital PCR is rapid, allows for quantitation of mutant alleles at very low concentrations, and is relatively inexpensive. However, it requires a priori knowledge of the specific mutations of interest and cannot be used to detect rearrangements unless the exact genomic breakpoint is known, and multiplex analysis of more than a few mutations is challenging [16]. Hybrid capture-based NGS allows multiplex analysis of thousands of genomic positions and in addition to single nucleotide variants and short insertions/deletions can readily detect rearrangements and copy number variation. Recent advances in NGS technology have made it possible to achieve similar or even better analytical sensitivity for cfDNA detection as digital PCR through molecular barcoding and digital error suppression [16, 17]. However, NGS-based methods are relatively more expensive than digital PCR and have longer turnaround times.

Historically, analysis of a tissue biopsy has been the primary method used to study acquired resistance in lung cancer patients treated with targeted therapies [18–20]. However, the need to attain a repeat biopsy following progression is often a significant obstacle to performing such analyses. Recent studies have demonstrated that plasma cfDNA may be used for the early recognition and definition of mechanisms of acquired resistance to targeted agents in oncogene driven lung cancers [21, 22]. This includes detecting the emergence of EGFR T790M in plasma of patients with EGFR mutant lung cancers treated with erlotinib, which accounts for the majority of treatment failures [13]. The importance of studying acquired resistance mechanisms is further highlighted by the recent development of third-generation mutant-selective EGFR inhibitors used to overcome EGFR T790M, including osimertinib which has recently gained FDA approval and has been adopted as a standard of care [23]. In this setting, detection of T790M in plasma was shown to be just as predictive of osimertinib response as detection of T790M in tissue [2]. Additionally, novel resistance mechanisms to osimertinib and rociletinib such as EGFR C797S and L798I mutations, as well as previously described mechanisms such as MET amplification, and activating mutations in PIK3CA have been identified and/or characterized by sequencing of plasma cfDNA (Figure 2) [24, 25]. It is worth pointing out that, with longitudinal serial use of ultrasensitive plasma NGS assays, subclonal mutations may be detected before they become clinically relevant. In the recently reported AURA3 trial, plasma EGFR T790M status independently predicted improved outcomes for patients with EGFR mutant lung cancers who received osimertinib versus platinum/pemetrexed chemotherapy [26, 27]. However, it is still unclear whether there is benefit in initiating new targeted treatment early upon detection of plasma T790M at subclonal status when tissue T790M may well be negative, compared to the current standard of care of switching treatment only upon clinical progression of disease. Prospective clinical trials will be needed to answer this question.

Figure 2: Illustrative representation of the noninvasive and universally obtainable methods of liquid biopsy for ctDNA from plasma and CSF which can be sequenced to ascertain oncogenic drivers and resistance mechanisms.
Figure 2: Application of NGS-based ctDNA analysis for identification of mechanisms of acquired resistance in lung cancer patients treated with EGFR targeted therapies. Serial ctDNA measurements from four different patients with T790M mutant tumors treated with the third-generation T790M-selective EGFR tyrosine kinase inhibitor (TKI) rociletinib. Activating mutations in EGFR are shown in grey, the T790M resistance mutation is shown in blue, and emergent resistance alterations are shown in red. Serial ctDNA measurements were performed using the hybrid capture NGS-based Cancer Personalized Profiling by deep Sequencing (CAPP-Seq) approach [20].
genomic alterations which show promise for the monitoring of both primary CNS tumors and metastatic lesions [6]. Genotyping the primary tumor alone can miss substantial targeted therapy opportunities for CNS metastases; however, routine brain biopsies are simply unfeasible. Circulating tumor DNA (ctDNA) analysis of cerebrospinal fluid (CSF) is emerging as a novel approach to address this unmet need through a less invasive procedure, lumbar puncture, performed at the bedside or the neurooncologist’s office.

Several studies suggest that malignancy involving the CNS, be it a primary CNS tumor or a metastatic lesion, poses a unique challenge for acquisition of ctDNA representative of the central lesion in the peripheral blood as the shed material may not predictably cross the blood-brain barrier (BBB) [38, 39]. De Mattos-Arruda et al. showed that ctDNA was more abundant in the CSF and more representative of CNS tumor genetic mutational status than ctDNA from plasma in the same individual [9, 39]. There is also data demonstrating differences in resistance mechanisms to driver targeted therapy in the CNS versus periphery, thought to be attributable to reduced BBB penetration of the drug. This lower concentration of medication in the CSF allows for differences in selective pressure, leading to alternative mechanisms of resistance in the CNS compartment [40, 41]. In a cohort of 12 patients with progressive CNS disease burden on targeted therapy with TKIs (EGFR, ALK, HER2, or BRAF), 4 were found to have mutations on CSF ctDNA which conferred resistance to targeted treatment that was not otherwise seen in the periphery [19]. Parallel analyses of plasma and CSF pools can provide a unique and comprehensive view of tumor evolution in vivo. Determining the ideal time for CSF ctDNA testing is still under investigation in patients with lung cancers and CNS metastases. A concept is to consider CSF ctDNA analysis compared to plasma ctDNA when a patient has clinical progression in the CNS compartment discordant from the periphery to look for distinct mutational profile, as brain biopsy is most often not feasible in this setting. With the clinical development of CSF ctDNA, we can discover the genomic profile and evolution of CNS metastases without performing invasive brain biopsies and tailor CNS targeted treatments toward their specific genetic aberrations.

Given the noninvasive nature of liquid biopsy and the rapidly improving methodologies for detecting ctDNA, the ability for real-time minimally invasive monitoring of the emergence of resistance mechanisms is quickly becoming a reality. Therefore, we advocate for the incorporation of ctDNA analysis in clinical trials of targeted therapies for the systematic interrogation of genomic evolution of lung cancers. Continued clinical research is vital as we incorporate ctDNA into everyday clinical practice. Researches in optimization of timing, frequency, and choice of liquid biopsy testing in the clinical setting along with the ongoing technical refinements that are expected to bring down the cost of genetic sequencing from ctDNA are keys to help mitigate the financial toxicity for patients in the future. By capturing genomic evolution, ctDNA analysis could accelerate therapeutic discovery and deliver the next leap forward in precision medicine for patients with lung cancers and other solid tumors.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Acknowledgments
The authors would like to thank Lauren Goldblum for her assistance in creating the illustrations in Figure 1. The authors from the Memorial Sloan Kettering Cancer Center are supported by the Core Grant P30 CA008748 from the National Institutes of Health, USA.

References
[1] T. S. Mok, Y.-L. Wu, S. Thongprasert et al., “Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma,” The New England Journal of Medicine, vol. 361, no. 10, pp. 947–957, 2009.
[2] M. G. Kris, B. E. Johnson, L. D. Berry et al., “Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs,” JAMA, vol. 311, no. 19, pp. 1998–2006, 2014.
[3] T. S. Mok, Y.-L. Wu, S. Thongprasert et al., “Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma,” New England Journal of Medicine, vol. 361, no. 10, pp. 947–957, 2009.
[4] M. Greaves and C. C. Maley, “Clonal evolution in cancer,” Nature, vol. 481, no. 7381, pp. 306–313, 2012.
[5] R. M. Bambury, D. G. Power, and S. O’Reilly, “Intratumor heterogeneity and branched evolution,” The New England Journal of Medicine, vol. 366, no. 22, p. 2132, 2012.
[6] E. I. Pentsova, R. H. Shah, J. Tang et al., “Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid,” Journal of Clinical Oncology, vol. 34, no. 20, pp. 2404–2415, 2016.
[7] D. A. Haber, N. S. Gray, and J. Baselga, “The evolving war on cancer,” Cell, vol. 145, no. 1, pp. 19–24, 2011.
[8] J. C. Thompson, S. S. Yee, A. B. Troxel et al., “Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA,” Clinical Cancer Research, vol. 22, no. 23, pp. 5772–5782, 2016.
[9] L. De Mattos-Arruda, R. Mayor, C. K. Y. Ng et al., “Cerebrospinal fluid-derived circulating tumor DNA better represents the genomic alterations of brain tumors than plasma,” Nature Communications, vol. 6, article 8839, 2015.
[10] S. Chen, J. Zhao, L. Cui, and Y. Liu, “Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs,” Clinical and Translational Oncology, vol. 19, no. 3, pp. 332–340, 2017.
[11] D. Dressman, H. Yan, G. Traverso, K. W. Kinzler, and B. Vogelstein, “Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 15, pp. 8817–8822, 2003.
[12] F. Diehl, M. Li, Y. He, K. W. Kinzler, B. Vogelstein, and D. Dressman, “BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions,” Nature Methods, vol. 3, no. 7, pp. 551–559, 2006.
[13] G. R. Oxnard, C. P. Paweletz, Y. Kuang et al., “Noninvasive detection of response and resistance in EGFR-mutant lung
cancer using quantitative next-generation genotyping of cell-free plasma DNA,” *Clinical Cancer Research*, vol. 20, no. 6, pp. 1698–1705, 2014.

[14] S. Serrat`ı, S. De Summa, B. Pilato et al., “Next-generation sequencing: advances and applications in cancer diagnosis,” *OncoTargets and Therapy*, vol. Volume 9, pp. 7355–7365, 2016.

[15] D. Sie, P. J. F. Snijders, G. A. Meijer et al., “Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology,” *Cellular Oncology*, vol. 37, no. 5, pp. 353–361, 2014.

[16] A. M. Newman, S. V. Bratman, J. To et al., “An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage,” *Nature Medicine*, vol. 20, no. 5, pp. 548–554, 2014.

[17] A. M. Newman, A. F. Lovejoy, D. M. Klass et al., “Integrated digital error suppression for improved detection of circulating tumor DNA,” *Nature Biotechnology*, vol. 34, no. 5, pp. 547–555, 2016.

[18] L. V. Sequist, B. A. Waltman, D. Dias-Santagata et al., “Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors,” *Science Translational Medicine*, vol. 3, no. 75, p. 75ra26, 2011.

[19] H. A. Yu, M. E. Arcila, N. Rekhtman et al., “Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers,” *Clinical Cancer Research*, vol. 19, no. 8, pp. 2240–2247, 2013.

[20] K. Ohashi, L. V. Sequist, M. E. Arcila et al., “Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEKI,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 109, no. 31, pp. E2127–E2133, 2012.

[21] B. S. Sorensen, L. Wu, W. Wei et al., “Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib,” *Cancer*, vol. 120, no. 24, pp. 3896–3901, 2014.

[22] K. Taniguchi, J. Uchida, K. Nishino et al., “Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas,” *Clinical Cancer Research*, vol. 17, no. 24, pp. 7808–7815, 2011.

[23] P. A. Jäne, J. Chih-Hsin Yang, D.-W. Kim et al., “AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer,” *The New England Journal of Medicine*, vol. 372, no. 18, pp. 1689–1699, 2015.

[24] K. S. Thress, C. P. Paweletz, E. Felip et al., “Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M,” *Nature Medicine*, vol. 21, no. 6, pp. 560–562, 2015.

[25] J. J. Chabon, A. D. Simmons, A. F. Lovejoy et al., “Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients,” *Nature Communications*, vol. 7, Article ID 11815, 2016.

[26] T. S. Mok, Y. Wu, M. Ahn et al., “Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer,” *New England Journal of Medicine*, vol. 376, no. 7, pp. 629–640, 2017.

[27] Y. L. Wu, S. Jenkins, S. Ramalingam et al., “MA08.03 osimertinib vs platinum-pemetrexed for T790M-mutation positive advanced NSCLC (AURA3): plasma ctDNA analysis,” *Journal of Thoracic Oncology*, vol. 12, no. 1, p. S386, 2017.

[28] M. Murtaza, S.-J. Dawson, D. W. Y. Tsui et al., “Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA,” *Nature*, vol. 497, no. 7447, pp. 108–112, 2013.

[29] C. Uzun, Z. Akkaya, E. Dusunceli Atman et al., “Diagnostic accuracy and safety of CT-guided fine needle aspiration biopsy of pulmonary lesions with non-coaxial technique: a single center experience with 442 biopsies,” *Diagnostic and Interventional Radiology*, vol. 23, no. 2, pp. 137–143, 2017.

[30] Y. Yang, J. Jiang, X. Tan, and P. Tian, “CT-guided percutaneous transthoracic needle biopsy for paramediastinal and nonpara mediastinal lung lesions: diagnostic yield and complications in 1484 patients,” *Medicine*, vol. 95, no. 31, Article ID e4460, 2016.

[31] C. B. Laursen, T. M. H. Naur, U. Bodtger et al., “Ultrasound-guided lung biopsy in the hands of respiratory physicians: diagnostic yield and complications in 215 consecutive patients in 3 centers,” *Journal of Bronchology and Interventional Pulmonology*, vol. 23, no. 3, pp. 220–228, 2016.

[32] M. J. Overman, J. Modak, S. Kopetz et al., “Use of research biopsies in clinical trials: are risks and benefits adequately discussed?,” vol. 31, no. 1, pp. 17–22, 2013.

[33] W. Sun, X. Yuan, Y. Tian et al., “Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer,” *Journal of Hematology & Oncology*, vol. 8, article 95, 2015.

[34] W. Sun, X. Yuan, Y. Tian et al., “Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer,” *Journal of Hematology and Oncology*, vol. 8, no. 1, article 95, 2015.

[35] A. G. Sacher, C. Paweletz, S. E. Dahlberg et al., “Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer,” *JAMA Oncology*, vol. 2, no. 8, article 104, 2016.

[36] J. Sherwood, S. Dearden, M. Ratcliffe, and J. Walker, “Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review,” *Journal of Experimental and Clinical Cancer Research*, vol. 34, article 92, 2015.

[37] P. Brastianos, S. Carter, S. Santagata et al., “2905 Genomic characterization of brain metastases and paired primary tumors reveals branched evolution and potential therapeutic targets,” *European Journal of Cancer*, vol. 51, supplement 3, p. S586, 2015.

[38] C. Bettegowda, M. Sausen, R. J. Leary et al., “Detection of circulating tumor DNA in early- and late-stage human malignancies,” *Science Translational Medicine*, vol. 6, Article ID 224ra24, 2014.

[39] C. L. Weston, M. J. Glantz, and J. R. Connor, “Detection of cancer cells in the cerebrospinal fluid: current methods and future directions,” *Fluids and Barriers of the CNS*, vol. 8, no. 1, article 14, 2011.

[40] T. Kawamura, A. Hata, J. Takeshita et al., “High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs,” *Cancer Chemotherapy and Pharmacology*, vol. 75, no. 6, pp. 1261–1266, 2015.

[41] C. Grommes, G. R. Oxnard, M. G. Kris et al., “Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer,” *Neuro-Oncology*, vol. 13, no. 12, pp. 1364–1369, 2011.